Abstract
The present industry update covers the period 1–31 October 2013, with information sourced from company press releases, regulatory and patent agencies as well as the scientific literature. Despite this section being dedicated to advances in ‘man-made’ drug delivery, it is notable that this year’s Nobel Prize in Physiology or Medicine was awarded for the exploration of cells’ vesicle transport systems, which deliver necessary cargo from one place to another in an intricate, scheduled manner. The operation of the system as a whole could have implications for drug delivery and numerous nanomedicine drug-delivery applications are mimicking nature, such as the recent accomplishment in siRNA drug delivery by Alnylam and Arrowhead as well as hydrogel, nanoparticle and conjugation concepts such as Synta´s Hsp90. Notably the US FDA is picking up with regulatory requirements in this field as mentioned in their FDA Voice Blog. Biotechnology initial public offerings and venture capitalist deals gained momentum this year; the top list is far more extensive but also far more competitive. Recent examples in the drug delivery domain are Svelte, Enteris, Allercan and others.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
